Literature DB >> 11384107

Telomerase activity and p53-dependent apoptosis in ovarian cancer cells.

R Akeshima1, J Kigawa, M Takahashi, T Oishi, Y Kanamori, H Itamochi, M Shimada, S Kamazawa, S Sato, N Terakawa.   

Abstract

We conducted the present study to determine the relationship between p53-dependent apoptosis and telomerase activity in ovarian cancer cells. A human ovarian adenocarcinoma cell line, SK-OV-3 that had homozygous deletion of the p53 gene was used in this study. Wild-type p53 genes were transducted to SK-OV-3 cells with a recombinant adenovirus that contained a wild-type p53 gene (AxCAp53). IC(50)to cisplatin (CDDP) was 12.9 microM for SK-OV-3 cells and 9.2 microM for p53 gene-transducted SK-OV-3 cells. The apoptotic index for cells with p53 gene transduction was significantly higher than cells without transduction. Additionally, p53 gene transduction significantly enhanced CDDP-induced apoptosis. Bax protein in SK-OV-3 cells did not differ before and after exposure to CDDP. In SK-OV-3 cells with transduction of the p53 gene, the expression of p53 and Bax proteins increased after exposure to CDDP. Expression of Bcl-xL decreased after exposure to CDDP in SK-OV-3 cells with and without transduction. The telomerase activity in SK-OV-3 cells with the p53 gene was significantly lower compared with the cells without the p53 gene. CDDP exposure did not affect telomerase activity and human telomerase reverse transcriptase (hTERT) expression in both cell lines. We suggest that the p53 gene may relate to telomerase activity, but that p53-dependent apoptosis does not affect the activity. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384107      PMCID: PMC2363666          DOI: 10.1054/bjoc.2001.1812

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Inhibition of telomerase activity by cisplatin in human testicular cancer cells.

Authors:  A M Burger; J A Double; D R Newell
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

2.  Telomerase activity in immortalized endothelial cells undergoing p53-mediated apoptosis.

Authors:  S A Maxwell; D Capp; S A Acosta
Journal:  Biochem Biophys Res Commun       Date:  1997-12-29       Impact factor: 3.575

3.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

Review 4.  Telomerase, cell immortality, and cancer.

Authors:  C B Harley; N W Kim; K R Prowse; S L Weinrich; K S Hirsch; M D West; S Bacchetti; H W Hirte; C M Counter; C W Greider
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

5.  Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.

Authors:  M Fritsche; C Haessler; G Brandner
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

6.  Bcl-2 modulates telomerase activity.

Authors:  M Mandal; R Kumar
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

7.  Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas.

Authors:  J Nakayama; H Tahara; E Tahara; M Saito; K Ito; H Nakamura; T Nakanishi; E Tahara; T Ide; F Ishikawa
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

8.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

9.  A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

Authors:  S C Righetti; G Della Torre; S Pilotti; S Ménard; F Ottone; M I Colnaghi; M A Pierotti; C Lavarino; M Cornarotti; S Oriana; S Böhm; G L Bresciani; G Spatti; F Zunino
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

10.  Expression and prognostic significance of Bcl-2 in ovarian tumours.

Authors:  R Henriksen; E Wilander; K Oberg
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more
  1 in total

Review 1.  Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer.

Authors:  Jae-Il Roh; Young Hoon Sung; Han-Woong Lee
Journal:  Onco Targets Ther       Date:  2013-08-26       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.